Morgan Stanley Global Endurance C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Morgan Stanley Global Endurance Portfolio Class C MSJCX
- NAV / 1-Day Return 21.51 / −0.65 %
- Total Assets 15.5M
-
Adj. Expense Ratio
2.100%
- Expense Ratio 2.100%
- Distribution Fee Level Above Average
- Share Class Type Level Load
- Category Global Small/Mid Stock
- Investment Style Small Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.00
- Turnover 176%
USD | NAV as of Jul 15, 2026 | 1-Day Return as of Jul 15, 2026, 12:11 AM GMT+0
Morningstar’s Analysis MSJCX
Will MSJCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Roivant Sciences Ltd Ordinary Shares | 8.73 | 1M | Healthcare |
Victoria PLC | 7.88 | 1M | Consumer Cyclical |
QXO Inc | 5.36 | 833,662 | Industrials |
Teleflex Inc | 5.13 | 797,799 | Healthcare |
Immunovant Inc | 4.66 | 724,459 | Healthcare |
Calumet Inc | 4.65 | 723,636 | Basic Materials |
Arbutus Biopharma Corp | 4.28 | 666,396 | Healthcare |
Appian Corp Class A | 4.18 | 650,440 | Technology |
Floor & Decor Holdings Inc Class A | 3.76 | 585,267 | Consumer Cyclical |
Royalty Pharma PLC Class A | 3.18 | 494,235 | Healthcare |